Post-approval safety issues with innovative drugs: A European cohort study

Drug Safety

Volumn 36, Issue 11, 2013, Pages 1105-1115

  Mol, Peter G M ^a,b   Arnardottir, Arna H ^a   Motola, Domenico ^c   Vrijlandt, Patrick J ^b   Duijnhoven, Ruben G ^b,d   Haaijer Ruskamp, Flora M ^a   De Graeff, Pieter A ^a,b   Denig, Petra ^a   Straus, Sabine M J M ^b,e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UTRECHT UNIVERSITY   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CONSENSUS INTERFERON; DOFETILIDE; EFALIZUMAB; FOMIVIRSEN; RIMONABANT; ROSIGLITAZONE; SITAXSENTAN; VALDECOXIB;

ARTICLE; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; EUROPE; FOLLOW UP; HEALTH CARE PERSONNEL; PRIORITY JOURNAL;

ALGORITHMS; COHORT STUDIES; CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PROPORTIONAL HAZARDS MODELS; SAFETY-BASED DRUG WITHDRAWALS;

EID: 84887138391     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0094-y     Document Type: Article

References (27)

1. Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2007;16(1):5-16.
2. Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJM, de Graeff PA, Mol PG. Safety issues of HIV drugs, regulatory consequences. Drug Saf. 2011;34(11):1101-14.
3. Stefansdottir G, Knol MJ, Arnardottir AH, van der Elst ME, Grobbee DE, Leufkens HG, et al. Safety learning from drugs of the same class: room for improvement. Clin Pharmacol Ther. 2012;91(5):872-80.
4. Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol. 2006;62(5):610-6.
5. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf. 2010;33(6):463-74.
6. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354-61.
7. Moore TJ, Furberg CD. The safety risks of innovation: the FDA's Expedited Drug Development Pathway. JAMA. 2012;308(9):869-70.
8. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172(21):1680-1.
9. Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG. Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol. 2011;72(3):490-9.
10. Boon WP, Moors EH, Meijer A, Schellekens H. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther. 2010;88(6):848-53.
11. Tavassoli N, Montastruc J. Is there any relationship between actual benefit and added value of drugs and pharmacovigilance alerts? Br J Clin Pharmacol. 2009;68(1):124-5.
12. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577-81.
13. Heemstra HE, Giezen TJ, Mantel-Teeuwisse AK, de Vrueh RL, Leufkens HG. Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study. Drug Saf. 2010;33(2):127-37.
14. Motola D, De Ponti F, Rossi P, Martini N, Montanaro N. Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol. 2004;59(4):475-8.
15. Eichler HG, Aronsson B, Abadie E, Salmonson T. New drug approval success rate in Europe in 2009. Nat Rev Drug Discov. 2010;9(5):355-6.
16. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, Schellekens H, Leufkens HGM, Egberts ACG. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300(16):1887-96.
17. Duijnhoven RG, Raine JM, Straus SMJM, De Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med. 2013;10(3):e1001407.
18. Lexchin J. International comparison of assessments of pharmaceutical innovation. Health Policy. 2012;105(2-3):221-5.
19. Morrato EH, Staffa JA. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. Pharmacoepidemiol Drug Saf. 2007;16(1):104-12.
20. Morrato EH, Ling SB. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA. Med Care. 2012;50(11):970-86.
21. Raine J, Wise L, Blackburn S, Eichler HG, Breckenridge A. European perspective on risk management and drug safety. Clin Pharmacol Ther. 2011;89(5):650-4.
22. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009;27(26):4398-405.
23. Leveque D. Off-label use of anticancer drugs. Lancet Oncol. 2008;9(11):1102-7.
24. Regnier S. What is the value of 'me-too' drugs? Health Care Manage Sci (Epub 26 Feb 2013).
25. Hollis A. Me-too drugs: is there a problem? 2004. http://www.who.int/ intellectualproperty/topics/ip/Me-tooDrugs-Hollis1.pdf (Accessed 25 June 2013).
26. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-7.
27. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191-200.